AKBA: Gunggung utang perusahaan Akebia Therapeutics, Inc.

Akebia Therapeutics (AKBA) develops comprehensive kidney therapy solutions, where high development costs and patent protection block new entrants. The price action history on GURU.Markets, which recorded the 0.21 metric, links these barriers to the creation of a treatment system that makes patients dependent on the brand's products. Simultaneously, the company is fighting for profitable market segments by displacing similar analogs.

AKBA: Utang perusahaan Akebia Therapeutics 04.07.2022 - 01.11.2026

Akebia Therapeutics, Inc. (AKBA) - rincian metrik lan laporan keuangan

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega Akebia Corp|AKBA - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar Akebia|AKBA - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Nilai Akuntansi Saham Akebia Therapeutics|AKBA - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih akebia.com|AKBA - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal Akebia Therapeutics|AKBA - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Akebia Therapeutics Inc|AKBA - Utang perusahaan|Utang-utang marang kapitalisasi buku Akebia|AKBA - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Akebia Therapeutics|Rasio likuiditas darurat akebia.com

- informasi bathi lan kelipatan valuasi:

AKBA - Bathi resik perusahaan

Analisis fundamental perusahaan:AKBA Akebia Corp

Produk mawa merek Akebia Therapeutics Inc

An investment audit of the issuer requires a detailed examination of the debt load before opening a position. This metric aggregates short-term and long-term liabilities, determining the business's overall financial dependence on borrowed capital. For Akebia Therapeutics (AKBA), this is critical when scaling sales of drugs for dialysis centers in the US. Debt service dynamics against a backdrop of growing demand determine the company's stability. The debt volume history clearly reflects this balance.

Perusahaan pesaing

TVTX (Travere Corp) - Kewajiban utang agregat|Gunggung utang perusahaan ARDX (Ardelyx, Inc.)|Gunggung utang perusahaan prokidney.com PROK|TVRD - Utang perusahaan|Kewajiban utang agregat DMAC (DiaMedica Therapeutics Inc)|Unicycive (UNCY) - Utang perusahaan|Gunggung utang perusahaan rockwellmed.com|CVKD (Cadrenal Therapeutics) - Gunggung utang perusahaan|Gunggung utang perusahaan conduitpharma.com|Gunggung utang perusahaan CALT (Calliditas Therapeutics)|RNLX (Renalytix Plc) - Kewajiban utang agregat|Utang perusahaan ZyVersa Therapeutics, Inc. ZVSA